Ozempic and Wegovy: Scientists Uncover New Risks of Popular Weight-Loss “Miracle Drugs”
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,
GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions
Ozempic and Wegovy are helping many Americans lose weight, but they also may have other beneficial uses
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease and psychotic disorders.
Ozempic and Wegovy selected for next round of Medicare drug price negotiations
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
Wegovy and Ozempic top list of 15 drugs up for next price negotiations
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of federal price negotiations, which are scheduled to begin this year, with resulting bargained prices going into effect in 2027.
Medicare drug price negotiations to target Ozempic, Wegovy and other drugs
The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.
Ozempic, Wegovy and other drugs are among 15 selected for Medicare’s price negotiations
The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers.
Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risks
Several years ago, a little-known drug named Ozempic – previously used only to treat diabetes – emerged as a promising new drug for weight management. The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists,
The Health Risks and Benefits of Weight-Loss Drugs
The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight.In report published in Nature Medicine,
'Miracle' drug innovation could see a new Wegovy launch every couple of years, Larry Summers says
Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of ...
New State Treasurer Brad Briner on Wegovy coverage, premium hikes and NC pension fund
Two weeks into the job, it’s clear that newly elected State Treasurer Brad Briner won’t shy away from taking action, even if ...
Outsourcing-pharma2d
Novo Nordisk reports positive results for high-dose Wegovy formulation
Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...
Hosted on MSN1d
High-Strength Wegovy; Aldosteronism Outcome Definitions; Insulin Unit Price Down 42%
Average price per insulin unit dropped 42%, from $0.33 in 2019 to $0.19 in mid-2024 -- the lowest average recorded in a ...
BioSpace1d
Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...